Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Change in Receivables (2023 - 2025)

Krystal Biotech (KRYS) has disclosed Change in Receivables for 3 consecutive years, with -$2.5 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 133.45% to -$2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.1 million through Dec 2025, down 64.72% year-over-year, with the annual reading at $22.1 million for FY2025, 64.72% down from the prior year.
  • Change in Receivables hit -$2.5 million in Q4 2025 for Krystal Biotech, down from $17.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $56.8 million in Q2 2024 to a low of -$5.9 million in Q3 2024.
  • Historically, Change in Receivables has averaged $12.7 million across 3 years, with a median of $7.8 million in 2024.
  • Biggest five-year swings in Change in Receivables: plummeted 163.75% in 2024 and later skyrocketed 401.78% in 2025.
  • Year by year, Change in Receivables stood at $32.7 million in 2023, then tumbled by 77.24% to $7.4 million in 2024, then plummeted by 133.45% to -$2.5 million in 2025.
  • Business Quant data shows Change in Receivables for KRYS at -$2.5 million in Q4 2025, $17.9 million in Q3 2025, and $8.2 million in Q2 2025.